Table 2.
Classification of eyes with neovascular age-related macular degeneration according to detection group of choroidal neovascularization (CNV).
| Group A (Well Circumscribed) | Group B (Moderately Circumscribed) | Group C (Poorly Circumscribed) | p-Value | |
|---|---|---|---|---|
| No. of eyes | 18 | 24 | 10 | - |
| Mean age, years | 74.5 ± 2.0 | 72.8 ± 9.4 | 71.9 ± 9.3 | 0.687 * |
| Sex (female, %) | 10 (55.6) | 9 (37.5) | 5 (50) | 0.491 † |
| BCVA, logMAR | 0.63 ± 0.40 | 0.45 ± 0.30 | 0.51 ± 0.49 | 0.279 ‡ |
| IOP, mmHg | 14.2 ± 3.3 | 15.0 ± 3.1 | 15.8 ± 4.0 | 0.221 ‡ |
| No. of treatment naive eyes | 2 | 5 | 0 | 0.326 § |
| No. of intravitreal injection | 4.2 ± 3.4 | 6.2 ± 5.2 | 6.2 ± 4.7 | 0.838 ‡ |
| Disease duration, months | 14.5 ± 14.1 | 17.9 ± 15.6 | 18.9 ± 14.6 | 0.524 ‡ |
| PED max height, μm | 167.2 ± 167.3 | 163.6 ± 144.9 | 174.7 ± 115.5 | 0.515 ‡ |
| PED max width, μm | 2493.4 ± 1364.6 | 2425.7 ± 1425.2 | 1926.0 ± 1317.7 | 0.421 ‡ |
| Choroidal thickness, μm | 210.0 ± 81.6 | 213.9 ± 103.6 | 235.4 ± 118.7 | 0.422 ‡ |
| Central fovea thickness, μm | 203.0 ± 65.7 | 297.5 ± 179.1 | 272.7 ± 121.7 | 0.534 ‡ |
| CNV area, mm2 | 2.2 ± 1.3 | 1.9 ± 2.5 | - | 0.816 ∥ |
| SRF existence, no. of eyes | 7 | 13 | 4 | 0.561 † |
| SRF height in eyes with SRF, μm | 135.7 ± 76.9 | 100.8 ± 62.5 | 106.0 ± 56.4 | 0.492 ‡ |
BCVA: best-corrected visual acuity; IOP: intraocular pressure; PED: pigment epithelial detachment (serous or vascularized); CNV: choroidal neovascularization; SRF: subretinal fluid. * one-way ANOVA; † Chi square test; ‡ Kruskal–Wallis test; § Fisher’s exact test; ∥ independent t-test.